Prophylaxis therapy with bypassing agents in patients with haemophilia A and inhibitors undergoing surgery: A cost analysis in Spain.
Eur J Haematol
; 105(1): 94-100, 2020 Jul.
Article
em En
| MEDLINE
| ID: mdl-32220097
ABSTRACT
OBJECTIVES:
This study estimated the cost of prophylaxis with activated prothrombin complex concentrate (aPCC) and recombinant activated factor VIIa (rFVIIa) in surgical patients with haemophilia A and inhibitors in Spain.METHODS:
A decision-analytic model was developed to estimate the cost to the Spanish National Health System of providing haemostatic coverage in this haemophilia population, with age distribution and average weight derived from the literature, and the annual number of surgeries (0.33 per patient) from local data. Drug costs were calculated from official ex-factory prices with a 7.5% mandatory deduction and recommended dosing regimens.RESULTS:
The estimated average costs per patient were 10 100.73 (aPCC) and 14 265.89 (rFVIIa) for dental extraction, 24 043.88 (aPCC) and 62 301.08 (rFVIIa) for minor surgery and 126 595.81 (aPCC) and 347 731.09 (rFVIIa) for major surgery. Assuming an estimated 23 annual surgeries in this population (N = 69), distributed as 19% dental extraction, 50% minor surgery and 31% major surgery, the total annual cost of prophylaxis was 1 209 682.35 with aPCC and 3 221 929.28 with rFVIIa.CONCLUSIONS:
aPCC costs were 62.5% lower than rFVIIa. Assuming potential clinical equivalence, aPCC is a potentially cost-saving option for surgical patients with haemophilia A and inhibitors.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Fator VIIa
/
Custos de Medicamentos
/
Inibidores dos Fatores de Coagulação Sanguínea
/
Hemofilia A
/
Hemorragia
/
Isoanticorpos
Tipo de estudo:
Health_economic_evaluation
/
Prognostic_studies
Limite:
Humans
País/Região como assunto:
Europa
Idioma:
En
Revista:
Eur J Haematol
Assunto da revista:
HEMATOLOGIA
Ano de publicação:
2020
Tipo de documento:
Article
País de afiliação:
Espanha